Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma.

Genome-wide association studies (GWAS) have so far identified 25 loci associated with glioma risk, with most showing specificity for either glioblastoma (GBM) or non-GBM tumors. The majority of these GWAS susceptibility variants reside in noncoding regions and the causal genes underlying the associations are largely unknown. Here we performed a transcriptome-wide association study to search for novel risk loci and candidate causal genes at known GWAS loci using Genotype-Tissue Expression Project (GTEx) data to predict cis-predicted gene expression in relation to GBM and non-GBM risk in conjunction with GWAS summary statistics on 12,488 glioma cases (6,183 GBM and 5,820 non-GBM) and 18,169 controls. Imposing a Bonferroni-corrected significance level of P < 5.69 × 10-6, we identified 31 genes, including GALNT6 at 12q13.33, as a candidate novel risk locus for GBM (mean Z = 4.43; P = 5.68 × 10-6). GALNT6 resides at least 55 Mb away from any previously identified glioma risk variant, while all other 30 significantly associated genes were located within 1 Mb of known GWAS-identified loci and were not significant after conditioning on the known GWAS-identified variants. These data identify a novel locus (GALNT6 at 12q13.33) and 30 genes at 12 known glioma risk loci associated with glioma risk, providing further insights into glioma tumorigenesis. SIGNIFICANCE: This study identifies new genes associated with glioma risk, increasing understanding of how these tumors develop.

[1]  Tarik Tihan,et al.  Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium , 2008, Cancer.

[2]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[3]  M. Wolter,et al.  Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas , 2010, International journal of cancer.

[4]  Jeffery M. Meyer,et al.  A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer , 2018, Nature Genetics.

[5]  Behrooz Torabi Moghadam,et al.  Genetic predisposition to mosaic Y chromosome loss in blood , 2019, Nature.

[6]  H. Juan,et al.  GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity , 2017, Oncotarget.

[7]  Yu Cheng,et al.  lncRNAs PVT1 and HAR1A are prognosis biomarkers and indicate therapy outcome for diffuse glioma patients , 2017, Oncotarget.

[8]  Harvey Risch,et al.  A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. , 2018, Cancer research.

[9]  V. Zoldoš,et al.  Glyco-genes change expression in cancer through aberrant methylation. , 2016, Biochimica et biophysica acta.

[10]  C. Martínez-A,et al.  DIDO as a Switchboard that Regulates Self-Renewal and Differentiation in Embryonic Stem Cells , 2017, Stem cell reports.

[11]  Hugues Sicotte,et al.  Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors , 2017, Nature Genetics.

[12]  Todd L Edwards,et al.  Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics , 2018, Nature Communications.

[13]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[14]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[15]  O. Delaneau,et al.  Estimating the causal tissues for complex traits and diseases , 2016, Nature Genetics.

[16]  M. Katoh,et al.  Identification and characterization of human TMEM25 and mouse Tmem25 genes in silico. , 2004, Oncology reports.

[17]  R. Henriksson,et al.  The Genetic Architecture of Gliomagenesis–Genetic Risk Variants Linked to Specific Molecular Subtypes , 2019, Cancers.

[18]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[19]  K. Hoang-Xuan,et al.  Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci , 2018, Acta Neuropathologica.

[20]  R. Houlston,et al.  Genome-wide association studies of cancer: current insights and future perspectives , 2017, Nature Reviews Cancer.

[21]  P. Visscher,et al.  Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits , 2012, Nature Genetics.

[22]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[23]  J. Joung,et al.  Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage , 2014, Genes & development.

[24]  H. Pickett,et al.  A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase , 2015, PLoS genetics.

[25]  Kari Stefansson,et al.  A germline variant in the TP53 polyadenylation signal confers cancer susceptibility , 2011, Nature Genetics.